IUdR/BUdR Cell Cycle Labelling

Cell Cycle Kinetics in Vivo in Patients With Hematologic Malignancies Studied by Iododeoxyuridine and Bromodeoxyuridine Labelling

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00042250

Enrollment

Registered

2002-07-26

Start date

1992-05-31

Completion date

2002-10-31

Last updated

2012-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic Malignancies

Keywords

Cell Cycle Interphase, G0, G1, G2, S Phase

Brief summary

To determine cell cycle parameters and changes after treatment, the labelling agent is given and a bone marrow aspiration is accomplished before treatment and after treatment for comparison. Participants must be undergoing concurrent therapy for hematologic malignancy.

Detailed description

Cell cycle parameters include LI, Ts, Tc, T dpot, changes in these parameters, and differences between normal and leukemic cells in patients with hematologic malignancy prior to and following treatment.

Interventions

DRUGChemotherapy for hematologic malignancy

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Histologic proof of one of: * AML, ALL, or AUL * MDS or CMML * CML * OR undergoing bone marrow transplantation. Participants should be: * off therapy for at least two weeks * At least 18 years old or older * Using adequate contraception if of child-bearing capability.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026